Roche Diagnostics reports that it will support the Oxford Biomedical Research Centre (OxBRC) in improved genetic and cytogenetic testing. 454’s next-generation sequencing technology and Roche NimbleGen’s high-density arrays will be used.
In the course of their research project, Oxford will install several 454 Genome Sequencer FLX systems and employ NimbleGen arrays as a preparative tool for sequencing and genome-wide detection of copy number variation.
The marriage of these new innovative technologies for clinical genetic testing will be thoroughly evaluated, according to Roche. Clinically documented samples ascertained for selected diseases will be tested in three areas: sequencing of several genes known for private familial mutations, mutation screening in a large number of genes, and identification of genes and regions with genomic imbalances.